Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1143
TNBC
Basal A
Nelfinavir
13099.174
uM
8.33740
12.98640
-0.8248 -1.0000 2.4791 0.2096
0.9823
0.9441
HCC1143
TNBC
Basal A
Nilotinib
ABL
nRTK
12112.145
uM
inf
inf
0.9353 0.9353 0.0000 0.0338
0.0179
1.9247
HCC1143
TNBC
Basal A
NSC 663284
CDC25
CDC
12112.159
uM
1.65580
2.04930
-0.8704 -0.8462 4.6458 0.6203
0.9973
1.8609
HCC1143
TNBC
Basal A
NU6102
CDK1/2
CDK
12112.147
uM
15.53550
42.20730
-0.2561 -1.0000 1.0992 0.2003
0.9510
1.8559
HCC1143
TNBC
Basal A
Nutlin 3a
MDM2
MDM2
7430.066
uM
43.83610
41.89710
0.2310 0.0707 3.3704 0.0403
0.9913
1.7623
HCC1143
TNBC
Basal A
Olomoucine II
CDK1
CDK
12112.147
uM
3.56240
6.1440
-0.5451 -0.5766 1.4072 0.3726
0.9979
1.8559
HCC1143
TNBC
Basal A
Omipalisib
PI3K
PI3K
7430.086
uM
0.04702
0.08855
-0.4404 -0.2887 0.7201 0.5752
0.9725
1.7884
HCC1143
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
7810.011
uM
17.43650
33.96740
-0.9111 -0.9647 1.6118 0.4304
0.9942
0.9243
HCC1143
TNBC
Basal A
Oxaliplatin
DNA cross-linker
DNA cross-linker
9233.12
uM
25.14560
41.16370
-0.8425 -0.8492 2.0140 0.3699
0.9982
1.1442
HCC1143
TNBC
Basal A
Oxamflatin
HDAC
HDAC
12112.147
uM
0.58530
2.00730
-0.7033 -0.8291 0.7933 0.5344
0.9882
1.8559
HCC1143
TNBC
Basal A
PD 98059
MEK
MAPK
12112.159
uM
305.83130
999.73550
0.6289 -0.3720 0.4696 0.0840
0.7922
1.8609
HCC1143
TNBC
Basal A
PD173074
FGFR1/3
RTK
7430.093
uM
13.84870
21.0130
-0.0291 -0.5045 1.6733 0.0825
0.9957
1.9432
HCC1143
TNBC
Basal A
PD184352
MEK
MAPK
12112.155
uM
inf
999.96340
0.7985 0.1935 0.3134 0.0636
0.7788
1.7965
HCC1143
TNBC
Basal A
PD184352
MEK
MAPK
12112.155
uM
inf
999.96340
0.7985 0.1935 0.3134 0.0636
0.7788
1.7965
HCC1143
TNBC
Basal A
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7430.095
uM
inf
inf
0.8459 0.8459 0.0000 0.1262
0.4872
1.9390
HCC1143
TNBC
Basal A
PS-1145
IKK
NFKB
7430.065
uM
inf
inf
0.9420 0.9420 0.0000 -0.0190
-0.3143
1.9263
HCC1143
TNBC
Basal A
Purvalanol A
CDK1
CDK
7430.067
uM
inf
35.48870
0.8725 0.8724 4.9993 -0.0048
0.5801
1.9308
HCC1143
TNBC
Basal A
QNZ
NFkB
NFKB
7430.096
uM
inf
0.02096
0.5504 0.5766 0.4766 0.2374
0.9622
2.0162
HCC1143
TNBC
Basal A
Ribavirin
15349.211
uM
inf
inf
0.8845 0.8845 0.0000 0.0438
-0.0616
1.2538
HCC1143
TNBC
Basal A
SB-3CT
MMP2/9
MMP
12112.144
uM
356.54910
1000.00000
0.6439 -0.2848 0.4371 0.0966
0.6441
1.9163
HCC1143
TNBC
Basal A
Selumetinib
MEK
MAPK
12112.155
uM
inf
0.16467
0.5706 0.6237 1.4639 0.1565
0.9624
1.7965
HCC1143
TNBC
Basal A
Sigma A6730
AKT
AKT
12112.158
uM
14.8090
23.94180
-0.8320 -1.0000 2.2869 0.2578
0.9630
1.8430
HCC1143
TNBC
Basal A
Sirolimus
MTOR
MTOR
7809.068
uM
1.18010
0.00577
0.3535 0.3928 0.2895 0.4238
0.7314
1.7208
HCC1143
TNBC
Basal A
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7430.085
uM
57.30850
69.22010
-0.7847 -0.7854 5.0000 0.1886
0.9971
1.9592
HCC1143
TNBC
Basal A
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7430.067
uM
8.47310
12.95630
-0.8826 -0.8843 2.3979 0.3564
0.9986
1.9308